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Loss of normal cyclical 2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients Kia Soong Tan, Lesley C McFarlane, Brian J Lipworth
Abstract
The role of female sex steroid hormones in asthma is still unclear, although there is much Background -A study was undertaken to investigate the influence of the menstrual circumstantial evidence to suggest that they may be important. Up to 40% of female asth-cycle on airway responsiveness and 2 adrenoceptor function in female asthmatic matic subjects report a premenstrual deterioration in their condition. [1] [2] [3] [4] Indeed, a patients. It has previously been shown that normal women exhibit cyclical changes in premenstrual fall in peak expiratory flow rate (PEFR) has been demonstrated even in those 2 adrenoceptor function with an increase in 2 adrenoceptor density in the luteal who have previously not been aware of this phenomenon. 4 An effect of sex steroid hor-phase during the premenstrual period. Methods -Fifteen women with stable, well mones has been shown by the observation that, in a few patients, intramuscular supplementary controlled asthma (mean forced expiratory volume in one second (FEV 1 ) 2.97 l progesterone eliminated the premenstrual fall in PEFR and allowed better control of asthma (93.8% predicted)) were evaluated. Measurements were made at the follicular phase with lower doses of systemic steroids. 5 However, the pathophysiology of this phenomenon (days 1-6) and the luteal phase (days 21-24) of the menstrual cycle. Airway re-remains unclear. Female sex steroid hormones have a regulatory role on 2 adrenoceptor func-sponsiveness was assessed using adenosine 5′-monophosphate (AMP) and expressed tion and it has been postulated that abnormal 2 adrenoceptor regulation may be a possible as PC 20 AMP. Beta 2 adrenoceptor function was evaluated by measuring lymphocyte mechanism for premenstrual asthma. We have previously shown that cyclical changes in 2 adrenoceptor parameters and constructing dose-response curves to sal-lymphocyte 2 adrenoceptor function occur during the menstrual cycle in normal women butamol (100-1600 g). The levels of female sex hormones were also measured with greater 2 adrenoceptor density and isoprenaline responsiveness in the luteal phase at both phases of the cycle. Results -There were significant increases during the premenstrual period. 6 Further support for this role is provided by in vitro studies in serum levels of both oestradiol (2.2-fold, p <0.001) and progesterone (7.2-fold, p which show that female sex steroid hormones potentiate the bronchorelaxant effect of cate-<0.05) between the follicular and luteal phases. Geometric mean PC 20 AMP was cholamines. 7 In this study we have investigated 2 ad-19.0 mg/ml and 7.6 mg/ml during the follicular and luteal phases, respectively (p renoceptor regulation and airway responsiveness to adenosine 5′-monophosphate <0.05), a 2.51-fold difference (95% CI 1.19 to 5.30) amounting to 1.33 doubling doses (AMP) in female asthmatic subjects. AMP was used because it is a marker of mediator release of AMP. There was no change in lymphocyte 2 adrenoceptor parameters or in from mast cells. 8 airway 2 adrenoceptor responses to salbutamol between the two phases.
Conclusions -Despite an appropriate rise Methods

sponsiveness.
had any documented history of subjective pre-menstrual deterioration in asthma control. The Subjects inhaled five breaths of normal saline control solution followed by sequential doub-median consumption of 2 agonist was 0.8 puffs/day and 10 subjects were receiving in-ling concentrations of AMP given at three minute intervals. FEV 1 was measured one minute haled corticosteroid in a median dose of 800 g beclomethasone daily (range 200-2000 g). after each administration of saline and AMP.
The test was terminated when a 20% fall in Two subjects were on oral theophyllines (250 mg and 600 mg daily). FEV 1 from the post-saline value was attained. A log-dose response curve was constructed and PC 20 was calculated by linear interpolation. Plasma levels of potassium (K) were meas-  Subjects kept a diary record of morning and ured by flame photometry (IL943 Analyser, Instrumentation Laboratory Ltd, Warrington, evening PEFR using a Wright's peak flow meter (Airmed, London, UK). The best of three UK) with analysis done at the end of the study and samples assayed in duplicate. The intra-successive readings was recorded. Subjects attended the laboratory on two separate days, assay and interassay coefficients of variation for analytical imprecision were 0.93% and 0.79%, during the follicular (days 1-6) and luteal (days 21-24) phases of the menstrual cycle, day 1 respectively.
Postural finger tremor was measured by a being the first day of the menses. Before each visit inhaled bronchodilators were withheld for previously validated method using an accelerometer transducer (Entran Ltd, Ealing, eight hours and long acting 2 agonists and oral theophyllines for 24 hours. Inhaled cortico-UK). 11 Four recordings were made and the results stored on a computer for subsequent steroids were continued unchanged. Both visits were made at the same time of day at 09.00 spectral analysis of total tremor power of more than 2 Hz (mg 2 /s) with computer assisted auto-hours.
At each visit an intravenous cannula was covariance. The mean of three consistent recordings was subsequently analysed. inserted into an antecubital vein, and after 30 minutes rest blood was removed for measure-Lymphocyte 2 adrenoceptor parameters included receptor density (Bmax), binding ment of serum levels of oestradiol and progesterone, eosinophil cationic protein (ECP) affinity (Kd), and maximal cAMP response to isoprenaline (Emax), measured as previously and lymphocyte 2 adrenoceptor parameters. Airway responsiveness to AMP was evaluated described. 6 In brief, 40 ml whole blood was collected into tubes containing ethylene-using a standard challenge protocol. After bronchial provocation subjects were rested until diamine tetraacetic acid diluted to 50 ml with phosphate buffered saline (PBS) and then FEV 1 returned to within ±5% of the baseline value. A dose-response curve to inhaled sal-two equal portions were centrifuged with 15 ml Lymphoprep (Nycomed Pharma AS, Oslo, butamol via a spacing device (Ventolin metered dose inhaler, Volumatic, Allen & Hanburys, Norway). The lymphocyte layer was removed and, after two further washes with PBS and Uxbridge, UK) was then constructed by giving cumulative doubling doses of 100 g, 200 g, centrifugation, the lymphocyte pellet was removed and resuspended in 5 ml PBS. Lympho-400 g, 800 g, and 1600 g. Measurements of FEV 1 , FEF 25-75 , plasma potassium levels and cyte Bmax and Kd were determined with 125 I-iodocyanopindolol (ICYP, NEN-DuPont postural finger tremor were made at baseline and 20 minutes after each dose increment, with (UK) Ltd, Stevenage, UK) at eight concentrations between 5 and 160 pmol/l. CGP each dose increment given every 30 minutes.
12177 (Ciba-Geigy, Basle, Switzerland) was added to half the tubes to prevent ICYP binding to receptor sites, thus allowing non-specific  FEV 1 and FEF 25-75 were measured according binding to be evaluated. Counts were determined with a gamma camera (LKB Wallac, to American Thoracic Society criteria 10 with a Vitalograph compact spirometer equipped with Wallac OY Pharmacia, Turku, Finland) and specific binding was calculated from total bind-a pneumotachograph head and pressure transducer, and on-line computer-assisted de-ing minus non-specific binding. The interassay coefficients of variation for analytical im-termination of FEV 1 and FEF 25-75 . Forced expiratory manoeuvres were performed from total precision were 10.3% for Bmax and 5.9% for Kd. A radioimmunoassay technique (Incstar, lung capacity to residual volume. The best FEV 1 value was taken from three consistent Stillwater, USA) was used to evaluate cyclic AMP levels (Emax) following suspension in measurements, and the FEF 25-75 was taken from the best test of three consistent forced ex-PBS containing theophylline (100 M) and bovine serum albumin and stimulation with piratory curves. A coefficient of variation of less than 3% was considered as acceptable.
isoprenaline 10 −4 M. The intra-assay and interassay coefficients of variation for analytical Bronchial challenge was performed using a Nebicheck nebuliser controller (PK Morgan imprecision were 2.7% and 10.2%, respectively. Ltd) with a System 22 Acorn nebuliser (Medic-Aid Ltd) with a driving pressure of 20 psi Serum levels of oestradiol (Sorin Biomedica, Saluggia, Italy), progesterone (Incstar, (138 kPa). The nebuliser was activated for 1.2 seconds from the initiation of inspiration. Fresh Stillwater, USA) and ECP (Pharmacia AB, Uppsala, Sweden) were measured by radio-solutions of adenosine 5′-monophosphate (AMP; Sigma, Poole, UK) were made up in immunoassay. The intra-assay coefficients of variation for analytical imprecision were 2.9%, normal saline on each study day in a range of concentrations from 0.04 mg/ml to 800 mg/ml. 6.3% and 6.3%, respectively. The subjects in our study showed a 2.5-fold salbutamol dose-response curve, and peak flow readings during the follicular and luteal increase in airway responsiveness to AMP in the phases of the menstrual cycle (n=15) luteal phase during the premenstrual period.
Discussion
Follicular Luteal
Previous studies have not shown any changes Progesterone (nmol/l) 1.9 (−2.9 to 6.6) 13.7 (8.9 to 18.5) * in airway responsiveness during the menstrual airway responsiveness changes but is also evid- * p<0.05; * * p<0.001. † Geometric mean values. ent in skin prick test reactions to histamine and allergen with greater weal and flare reactions during the early luteal phase. 15 Furthermore, it has recently been reported that hormone replacement therapy may increase the risk of developing asthma in postmenopausal women and this may be related to the dose of the   oestrogen component and duration of use. 16 PC 20 , Bmax, and finger tremor were log-trans-Our study has limitations which we reformed for analysis as these are not normally cognise. Firstly, we did not have a control group distributed. Effects on salbutamol dose-reof non-asthmatic subjects for comparison. The sponse curves were analysed as peak responses reason for this was that it would not be possible and area under the curve (AUC). Comparisons to compare PC 20 values in normal versus asthbetween the two phases were made by multimatic airways because of confounding effects factorial analysis of variance (MANOVA). A of airway geometry, even when using airways probability value of p <0.05 (two tailed) was conductance. Secondly, our patients were considered significant. stable and did not exhibit premenstrual asthma as such. Nonetheless, we felt at the outset that it would be valid to look at such patients as a way of investigating possible mechanisms for
Results
The results of all parameters are summarised sex hormone modulation of airway and receptor function. in table 1. There were significant increases in serum levels of both oestradiol (2.2-fold, p Despite an appropriate rise in luteal phase sex hormones in our group of asthmatic subjects, 2 <0.001) and progesterone (7.2-fold, p <0.05) between the follicular and luteal phases. Mean adrenoceptor parameters exhibited a loss of normal cyclical regulation previously described differences between the follicular and luteal phases were 179.3 pmol/l for oestradiol (95% in normal women. 6 It is unlikely that this is due to the effects of exposure to exogenous 2 confidence interval (CI) 112.4 to 246.1) and 11.8 nmol/l for progesterone (95% CI 5.1 to agonist as their drug consumption was minimal.
In this respect, we have recently shown that 18.6). Baseline FEV 1 (l) and FEF 25-75 (l/s) were not significantly different (2.77 versus 2.78 exogenous progesterone but not oestrogen upregulates follicular phase lymphocyte 2 ad-and 2.16 versus 2.34 (follicular versus luteal), respectively). There were significant changes renoceptor in normal women 17 and this raises the possibility that, in asthmatic patients, there in AMP responsiveness during the menstrual cycle with geometric mean PC 20 19.0 mg/ml may be subsensitivity to the postovulatory rise in endogenous progesterone. The lack of during the follicular phase and 7.6 mg/ml during the luteal phase (p <0.05), a 2.51-fold difference in serum ECP levels probably reflects the low levels observed in this group of stable difference (95% CI 1.19 to 5.30) amounting to 1.33 doubling doses. There was no significant patients with mild disease.
What is the clinical implication of our find-correlation between the cyclical change in PC 20 AMP and the changes in serum levels of oe-ings? In patients with stable asthma it is important to appreciate that the intrinsic stradiol (r 2 =0.17) or progesterone (r 2 =0.08).
Lymphocyte 2 adrenoceptor parameters and variability of bronchial hyperresponsiveness is such that PC 20 values can vary by up to twofold 2 adrenoceptor responses to salbutamol (as peak or AUC) were not altered during the -that is, one doubling dose. 18 Our findings in this study are therefore likely to have clinical menstrual cycle. Serum ECP levels did not differ between the two phases of the cycle and relevance as it exceeds the limit of biological variability. Hence, this change in airway re-domiciliary peak flow recordings did not show any changes during the menstrual cycle.
sponsiveness from the follicular to the luteal asthma or paediatric chronic obstructive pulmonary disphase may possibly explain the worsening ease. conceivable that these changes may be more 11 Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic clinically significant in patients with more patients. Lancet 1995;346:201-6. severe disease. Whether treatment for pre-12 Juniper EF, Kline PA, Roberts RS, Hargreave FE, Daniel EE. Airway responsiveness to methacholine during the menstrual asthma will involve drugs such as natural menstrual cycle and the effect of oral contheophylline, 19 sodium cromoglycate, 20 or
